Skip to content
Homepage
Autoimmune & Inflammatory Conditions

Psoriasis Treatment Options: Biologics, Topicals, Light Therapy, and Functional Approaches

Psoriasis treatments range from topical steroids to IL-23 inhibitor biologics that reach 90 percent skin clearance in up to 80 percent of patients with moderate to severe disease.

Explore the clinic directory
Published Updated
In this article
Psoriasis Treatment Options

Psoriasis treatment ranges from topical corticosteroids for a few isolated plaques to biologic injections that clear 90 percent of affected skin in 60 to 80 percent of patients with moderate to severe disease. The right starting point depends on body surface area, plaque location, and how the skin responds at each step, according to the joint American Academy of Dermatology and National Psoriasis Foundation guidelines (2019) [1].

At a Glance

  • Mild psoriasis (less than 3% BSA): topical corticosteroids and vitamin D analogs are first-line
  • Moderate psoriasis (3-10% BSA): phototherapy or targeted systemic agents
  • Moderate-to-severe (over 10% BSA or high-impact areas): biologics are the gold standard
  • IL-17 and IL-23 inhibitors achieve PASI 90 (90% improvement) in 60-80% of patients
  • Treatment ladders are no longer mandatory; guidelines now support early biologic use for appropriate candidates

Key takeaways

  • Treatment choice follows body surface area (BSA) and PASI score, but facial, genital, scalp, and nail plaques can justify systemic therapy even when BSA is low, according to AAD-NPF guidelines (2019) [1].
  • Topical corticosteroids and vitamin D analogs control an estimated 50 to 70 percent of mild psoriasis without systemic therapy.
  • Narrowband UVB phototherapy clears 60 to 80 percent of patients with consistent attendance, according to a systematic review of UV-based therapy (2013) [5].
  • IL-17 and IL-23 inhibitor biologics reach PASI 90 in 60 to 80 percent of patients, among the highest response rates of any psoriasis treatment class to date.
  • Treatment ladders that once required trying topicals and phototherapy before biologics are no longer mandatory; current guidelines support early biologic use for appropriate candidates.
  • Functional measures such as vitamin D optimization, gut health support, and stress reduction have supporting evidence as adjuncts, not as replacements for medical therapy.

How Psoriasis Treatment Is Categorized

Psoriasis treatment follows a severity-based framework. Body surface area (BSA), Psoriasis Area and Severity Index (PASI), and quality-of-life impact determine where you start [1]. But severity is not the only factor. Location matters: genital, facial, scalp, and nail psoriasis can justify systemic therapy even when BSA is low because of disproportionate functional and psychological impact.

The treatment landscape has changed dramatically in the past decade. Biologics that target specific immune pathways now achieve clearance rates that would have been unthinkable with older systemic agents. The question is no longer whether psoriasis can be controlled but which approach fits your disease profile, lifestyle, and risk tolerance.

Most people start this process with a dermatologist, though rheumatologists get involved when psoriatic arthritis is present. The psoriasis treatment guide on this site walks through how each option works in more detail, and the directory of clinics offering psoriasis treatment lists providers by location, not by paid placement: listing order is not a ranking that clinics buy, Featured slots are labeled and capped, Verified means a clinic completed the credential checks described in the site's vetting materials rather than paying for the badge, and browsing the directory itself is free for patients. For background on the condition itself, see the psoriasis condition overview.

Topical Treatments

Corticosteroids

The workhorse of mild psoriasis. Available in potencies from mild (hydrocortisone 1%) to super-potent (clobetasol propionate 0.05%). Vehicle matters: ointments are most potent, followed by creams, lotions, foams, and solutions [2].

Best practices:

  • Use mid-to-high potency for body plaques, low potency for face and skin folds
  • Apply once or twice daily during flares for 2-4 weeks
  • Taper to intermittent maintenance (2-3x/week) to prevent rebound
  • Avoid continuous high-potency use beyond 4 weeks to reduce atrophy risk

Expected outcome: 50-70% of mild psoriasis patients achieve adequate control with topicals alone.

Vitamin D Analogs (Calcipotriol, Calcitriol)

Slow keratinocyte proliferation and promote normal differentiation. Less effective than potent corticosteroids as monotherapy but valuable as combination partners. The calcipotriol/betamethasone combination (Enstilar, Taclonex) is one of the best-performing topical combinations in clinical trials [3].

Topical Retinoids (Tazarotene)

Normalizes keratinocyte differentiation. Can cause significant irritation, so it is often combined with a corticosteroid. Works well for nail and palmoplantar psoriasis. Apply every other night initially to build tolerance.

Calcineurin Inhibitors (Tacrolimus, Pimecrolimus)

Off-label for psoriasis but useful for facial and intertriginous (skin fold) psoriasis where steroid atrophy is a concern. They lack the efficacy for thick plaques but are safe for long-term use in sensitive areas.

Tapinarof (Vtama)

A newer topical aryl hydrocarbon receptor agonist approved in 2022 for plaque psoriasis. It offers a steroid-free option with no atrophy risk. PASI 75 rates of approximately 36-40% at 12 weeks in trials [4]. Useful for patients seeking to avoid steroids long-term.

Roflumilast Cream (Zoryve)

A topical PDE4 inhibitor approved in 2022. Effective for intertriginous psoriasis specifically. Lower efficacy than potent steroids for thick plaques but a good option for sensitive areas.

Phototherapy

Narrowband UVB (NB-UVB)

The standard phototherapy for psoriasis. Treatments 2-3 times weekly for 8-12 weeks in a light booth. Clearance rates of 60-80% are typical with consistent attendance [5].

Advantages: no systemic immunosuppression, safe in pregnancy, effective across all body areas. Disadvantages: requires frequent clinic visits (though home units are available by prescription), sunburn risk, long-term photodamage and theoretical skin cancer risk with cumulative exposure.

Excimer Laser (308 nm)

Targeted UVB delivery to individual plaques. Ideal for localized disease (fewer than 10% BSA). Higher doses can be delivered to plaques without exposing unaffected skin. Effective for stubborn plaques that resist topicals.

PUVA (Psoralen + UVA)

Once the gold standard, now used less frequently due to the increased skin cancer risk with cumulative treatments. Still useful for thick palmoplantar psoriasis and when NB-UVB fails. Limited to 150-200 lifetime treatments.

Traditional Systemic Agents

Methotrexate

The oldest systemic psoriasis therapy still in common use. Given weekly (oral or subcutaneous), it suppresses T-cell activation and keratinocyte proliferation. PASI 75 rates of 35-40% at 16 weeks [6].

Monitoring requirements: CBC, liver enzymes, and renal function every 8-12 weeks. Folate supplementation (1 mg daily or 5 mg the day after methotrexate) reduces side effects. Liver biopsy or FibroScan is recommended after cumulative dose of 3.5-4 g or if LFTs are persistently elevated.

Main advantages: inexpensive ($5-20/month generic), effective for psoriatic arthritis, long safety track record. Main disadvantages: hepatotoxicity risk, teratogenicity, fatigue, nausea, lower efficacy than biologics.

Cyclosporine

A calcineurin inhibitor that provides rapid disease control. PASI 75 in 50-70% of patients at 12-16 weeks. Limited to short courses (3-6 months maximum, ideally) due to nephrotoxicity and hypertension risk [7].

Best used as a “bridge” therapy: rapid disease control while transitioning to a biologic or other maintenance agent. Also useful for acute flares and erythrodermic psoriasis.

Acitretin

An oral retinoid. Modestly effective as monotherapy (PASI 75 in 25-30%) but highly effective combined with phototherapy. The combination of acitretin + NB-UVB is synergistic and allows lower UV doses.

Important: acitretin is teratogenic and has a 3-year washout period in women of childbearing potential (it converts to etretinate, which is stored in fat tissue). This makes it primarily used in postmenopausal women and men.

Apremilast (Otezla)

An oral PDE4 inhibitor. PASI 75 rates of 28-33% at 16 weeks, lower than biologics but with a more favorable safety profile and no immunosuppression monitoring [8]. Common side effects include nausea, diarrhea, headache, and weight loss (5 kg average in clinical trials).

Best suited for moderate psoriasis patients who prefer an oral medication and are not candidates for or decline biologics. Also approved for psoriatic arthritis.

Deucravacitinib (Sotyktu)

A selective TYK2 inhibitor approved in 2022. Oral, once-daily dosing. PASI 75 rates of 53-58% at 16 weeks, significantly outperforming apremilast in the head-to-head POETYK PSO-3 trial. No requirement for routine lab monitoring. Represents a new class of targeted oral systemic therapy that narrows the efficacy gap with biologics.

Biologic Therapies

Biologics target specific immune mediators driving psoriasis. They are the most effective treatments available and have transformed outcomes for moderate-to-severe disease.

TNF Inhibitors

The first-generation biologics for psoriasis.

  • Adalimumab (Humira/biosimilars): PASI 75 in 60-70%. Now available as less expensive biosimilars. Subcutaneous injection every 2 weeks.
  • Etanercept (Enbrel): PASI 75 in 45-55%. Oldest TNF inhibitor still used. Twice weekly initially, then weekly.
  • Infliximab (Remicade): PASI 75 in 75-80%. IV infusion at 0, 2, and 6 weeks, then every 8 weeks. Most potent TNF inhibitor but requires infusion center visits.
  • Certolizumab pegol (Cimzia): PASI 75 in 65-75%. Does not cross the placenta, making it the preferred biologic during pregnancy.

IL-17 Inhibitors

Higher efficacy than TNF inhibitors for skin psoriasis.

  • Secukinumab (Cosentyx): PASI 90 in 54-60%. Monthly subcutaneous injection after loading.
  • Ixekizumab (Taltz): PASI 90 in 65-71%. Biweekly loading, then monthly. Among the fastest-acting biologics.
  • Brodalumab (Siliq): PASI 100 (complete clearance) in 37-44%. Unique mechanism: blocks IL-17 receptor rather than the cytokine itself. Carries a boxed warning for suicidal ideation, though the causal relationship is debated [9].
  • Bimekizumab (Bimzelx): Dual IL-17A and IL-17F inhibitor. PASI 90 in 67-75% at 16 weeks. The most potent IL-17 agent available. Higher rate of oral candidiasis than single IL-17 inhibitors.

IL-23 Inhibitors

Target the upstream driver of the Th17 pathway. Fewer injections and durable responses.

  • Guselkumab (Tremfya): PASI 90 in 70-73%. Every 8 weeks after loading. Excellent durability of response.
  • Risankizumab (Skyrizi): PASI 90 in 72-75%. Every 12 weeks after loading. PASI 100 in 40-50%. Among the highest clearance rates of any biologic [10].
  • Tildrakizumab (Ilumya): PASI 90 in 35-45%. Less potent than guselkumab and risankizumab but good safety profile. Every 12 weeks.

IL-12/23 Inhibitor

  • Ustekinumab (Stelara): PASI 75 in 67-76%. Every 12 weeks after loading. Weight-based dosing. Long safety record (10+ years). Now outperformed by newer agents in head-to-head trials but still widely used. Biosimilars becoming available.

Choosing Between Treatments

The treatment decision should account for disease severity, location, comorbidities, patient preference, cost, and insurance coverage. A simplified decision framework:

ScenarioRecommended Approach
Mild, limited plaquesTopical steroids + calcipotriol
Mild with steroid concernsTapinarof, roflumilast, or calcineurin inhibitors
Moderate, widespreadPhototherapy or oral systemic (deucravacitinib, apremilast)
Moderate-to-severeIL-23 inhibitor (risankizumab, guselkumab) or IL-17 inhibitor
Severe with psoriatic arthritisIL-17 inhibitor, TNF inhibitor, or IL-23 inhibitor
Pregnancy or planningCertolizumab pegol (biologic); topicals and NB-UVB for mild cases
Rapid flare control neededCyclosporine bridge to biologic maintenance

Functional and Integrative Approaches

Alongside conventional treatment, these interventions have supporting evidence:

  • Stress reduction: Mindfulness-based stress reduction (MBSR) has been studied as a psoriasis adjunct. A small RCT showed faster clearance during phototherapy in the MBSR group.
  • Gut health optimization: Psoriasis patients show gut microbiome dysbiosis. Addressing gut health through diet, probiotics, and eliminating food sensitivities may reduce systemic inflammation.
  • Vitamin D optimization: Maintaining serum 25-OH vitamin D at 40-60 ng/mL. Deficiency is common in psoriasis and normalizing levels may reduce flare frequency.
  • Exercise: Regular moderate exercise reduces systemic inflammatory markers. 150 minutes/week of moderate activity is associated with improved psoriasis outcomes.

How Much Does Psoriasis Treatment Cost?

Cost varies enormously by treatment class and insurance coverage, and a meaningful share of psoriasis care is cash pay when a payer declines a specific agent or requires step therapy first. Topical corticosteroids and vitamin D analogs are typically the least expensive option, often available as low cost generics. Phototherapy adds the cost of clinic visits two to three times weekly, though some insurers cover a defined course and home NB-UVB units are available by prescription for patients who qualify.

Traditional oral systemics sit at the lower end of the systemic cost range. Methotrexate, for example, runs about $5-20 per month as a generic, though monitoring labs add to the total cost of care. Biologics are the most expensive class by list price, but most patients do not pay list price: manufacturer co-pay assistance programs and insurance exceptions to step therapy can substantially lower out of pocket cost for patients who qualify. Ask the prescribing clinic about co-pay cards and foundation assistance programs before assuming a biologic is out of reach financially.

Safety Considerations Across Psoriasis Treatments

Every psoriasis treatment carries a different risk profile, and matching that profile to a patient's health history is part of choosing the right option. Topical corticosteroids carry a risk of skin atrophy with prolonged high potency use, which is why tapering to intermittent maintenance matters. Phototherapy carries a theoretical long-term skin cancer risk tied to cumulative UV exposure, higher with PUVA than with narrowband UVB.

Traditional systemic agents require active monitoring: methotrexate needs periodic bloodwork for liver and kidney function, cyclosporine needs blood pressure and kidney function checks, and acitretin requires contraception planning in women of childbearing potential for three years after stopping the drug. Biologics suppress specific parts of the immune system rather than the whole immune system, so screening for latent tuberculosis and chronic infections before starting is standard practice, and vaccination status is typically reviewed first. No biologic or systemic agent is described by the FDA or by dermatology guidelines as free of risk, and the dermatologist who prescribes the medication is the right person to weigh individual factors such as pregnancy plans, liver disease, or a personal history of skin cancer.

Treatment Considerations by Psoriasis Subtype

Plaque psoriasis (psoriasis vulgaris) is the most common presentation and the one most of the guidance above addresses directly, but several subtypes call for an adjusted approach.

Guttate Psoriasis

Guttate psoriasis presents as small, drop-shaped lesions, often appearing after a streptococcal infection, and responds well to narrowband UVB or topical therapy in many cases. The guide to guttate psoriasis covers how it differs from plaque disease and when it resolves on its own.

Inverse Psoriasis

Inverse psoriasis affects skin folds such as the armpits, groin, and under the breasts, where thick steroid use raises atrophy risk quickly. Calcineurin inhibitors, roflumilast, and tapinarof are frequently preferred here; more detail is in the inverse psoriasis overview.

Pustular Psoriasis

Pustular psoriasis, including the generalized form, can require hospitalization and rapid systemic treatment such as cyclosporine or a biologic; it is not managed with topicals alone. The pustular psoriasis guide covers warning signs that call for urgent evaluation.

Nail Psoriasis

Nail psoriasis is notoriously slow to respond because nail growth itself is slow. Tazarotene, intralesional steroid injections, and biologics, particularly IL-17 and IL-23 inhibitors, tend to outperform topical steroids alone for nail involvement. The nail psoriasis treatment guide covers realistic timelines for improvement.

Frequently Asked Questions

What is the most effective treatment for psoriasis?

For moderate to severe plaque psoriasis, IL-17 and IL-23 inhibitor biologics produce the highest clearance rates currently available, with PASI 90 in 60 to 80 percent of patients across clinical trials. Effectiveness still depends on the individual: psoriatic arthritis, pregnancy plans, infection history, and cost or insurance coverage can all shift which agent is actually the best fit for a given patient.

Can psoriasis be treated without biologics?

Yes. Mild to moderate psoriasis is routinely controlled with topical corticosteroids, vitamin D analogs, phototherapy, or oral agents such as deucravacitinib and apremilast. Many patients never need a biologic; current guidelines reserve them for moderate to severe disease, high-impact locations, or cases where other options have not worked well enough.

How long does it take for psoriasis treatment to work?

Topical steroids can reduce redness and scaling within 2 to 4 weeks. Phototherapy typically takes 8 to 12 weeks of consistent sessions to show clearance. Biologics vary by class: IL-17 inhibitors such as ixekizumab act among the fastest, often showing improvement within the first few weeks, while IL-23 inhibitors build toward their full effect over 16 to 24 weeks.

Are biologics safe for long-term use?

Many biologics now have over a decade of post-marketing safety data, including ustekinumab and the TNF inhibitor class, and ongoing registries continue to track outcomes. They do raise infection risk because they suppress specific immune pathways, so screening for tuberculosis and other infections before starting, and monitoring after, is standard practice. No biologic is marketed as free of risk, and a prescribing dermatologist weighs that risk against the severity of untreated disease.

What is the first-line treatment for psoriasis?

For limited plaque psoriasis covering less than about 3 percent of body surface area, topical corticosteroids, often paired with a vitamin D analog, are the first-line approach according to AAD-NPF guidelines [1]. Phototherapy or a systemic agent moves up to first-line when disease is more extensive or affects the face, scalp, genitals, or nails regardless of total surface area.

Do diet and gut health changes actually help psoriasis?

Evidence is still developing. Psoriasis patients show measurable gut microbiome differences, and small studies link vitamin D optimization and stress reduction to fewer flares, but none of these approaches are a substitute for topical, light-based, or systemic therapy for active moderate to severe disease. They are reasonable adjuncts to discuss with a treating clinician, not a first-line replacement. The psoriasis diet guide covers which dietary changes have the most support.

Sources

  1. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072. doi:10.1016/j.jaad.2018.11.057 ↩
  2. Uva L, Miguel D, Pinheiro C, et al. Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol. 2012;2012:561018. doi:10.1155/2012/561018 ↩
  3. Kragballe K, Austad J, Barnes L, et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product. Br J Dermatol. 2006;154(6):1155-1160. doi:10.1111/j.1365-2133.2006.07231.x ↩
  4. Lebwohl MG, Stein Gold L, Strober B, et al. Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med. 2021;385(24):2219-2229. doi:10.1056/NEJMoa2103629 ↩
  5. Almutawa F, Alnomair N, Wang Y, et al. Systematic review of UV-based therapy for psoriasis. Am J Clin Dermatol. 2013;14(2):87-109. doi:10.1007/s40257-013-0015-y ↩
  6. Warren RB, Mrowietz U, von Kiedrowski R, et al. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP). Lancet. 2017;389(10068):528-537. doi:10.1016/S0140-6736(16)32127-4 ↩
  7. Griffiths CEM, Katsambas A, Dijkmans BAC, et al. Update on the use of ciclosporin in immune-mediated dermatoses. Br J Dermatol. 2006;155(Suppl 2):1-16. doi:10.1111/j.1365-2133.2006.07558.x ↩
  8. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73(6):1020-1026. doi:10.1136/annrheumdis-2013-205056 ↩
  9. Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318-1328. doi:10.1056/NEJMoa1503824 ↩
  10. Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2). Lancet. 2018;392(10148):650-661. doi:10.1016/S0140-6736(18)31713-6 ↩

Find clinics

Explore directory profiles by treatment and location.

Browse clinics

Explore the guides

Continue reading